We are live on
!
Find out more
PAI
Palo Alto Investors Portfolio holdings
AUM
$654M
1-Year Est. Return
77.8%
This Fund
S&P 500
This Quarter
Est. Return
+22.65%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.26B
AUM Growth
+$117M
(+10%)
Cap. Flow
-$20.7M
Cap. Flow
% of AUM
-1.63%
Top 10 Holdings %
Top 10 Hldgs %
85.03%
Holding
34
New
1
Increased
1
Reduced
6
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
eHealth
EHTH
|
+$2.26M |
| 2 |
PRVB
Provention Bio, Inc. Common Stock
PRVB
|
+$1.78M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
EPZM
Epizyme, Inc
EPZM
|
+$9.96M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$7.58M |
| 3 |
Vanda Pharmaceuticals
VNDA
|
+$3.43M |
| 4 |
Prothena Corp
PRTA
|
+$1M |
| 5 |
ABMD
Abiomed Inc
ABMD
|
+$984K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.37% |
| 2 | Financials | 0.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Mirum Pharmaceuticals
MIRM
$6.04B
| $1.36M | 0.11% |
64,700
| – | – |
|
|
ALIM
27
DELISTED
Alimera Sciences
ALIM
| $1.02M | 0.08% |
200,919
| – | – |
|
28
Aldeyra Therapeutics
ALDX
$91.7M
| $859K | 0.07% |
160,800
| – | – |
|
29
Dianthus Therapeutics
DNTH
$6.29B
| $610K | 0.05% |
27,019
| – | – |
|
30
Tactile Systems Technology
TCMD
$555M
| $211K | 0.02% |
27,100
| – | – |
|
|
MRNS
31
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $208K | 0.02% |
31,330
| – | – |
|
32
UroGen Pharma
URGN
$2.39B
| $204K | 0.02% |
24,500
| – | – |
|
33
Novavax
NVAX
$1.31B
| – | – |
-12,500
| Closed | -$643K |
|
|
EPZM
34
DELISTED
Epizyme, Inc
EPZM
| – | – |
-6,774,541
| Closed | -$9.96M |
|
Similar funds
AG
BL
PIM
ACA
PCM
HCM
ACM
DC
Palo Alto Investors's Q3 2022 Portfolio in Review
As of Q3 2022, Palo Alto Investors held 34 positions worth $1.26B, up 10% from $1.15B the previous quarter. Its ten largest holdings account for 85% of the portfolio.
Palo Alto Investors's Q3 2022 filing shows 1 new, 1 increased, 6 reduced and 2 closed positions. Its largest new stake was Provention Bio, Inc. Common Stock: 390,800 shares worth $1.76M. The largest sale was Epizyme, Inc, an estimated $9.96M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.
- Palo Alto Investors's largest Q3 2022 buy was Provention Bio, Inc. Common Stock: 390,800 shares worth $1.76M.
- Palo Alto Investors added most to eHealth in Q3 2022, an estimated $2.26M increase.
- Palo Alto Investors's biggest Q3 2022 reduction was BioMarin Pharmaceuticals, cutting an estimated $7.58M.
- Palo Alto Investors fully exited Epizyme, Inc in Q3 2022, selling an estimated $9.96M.
- Palo Alto Investors's ten largest holdings make up 85% of its $1.26B portfolio in Q3 2022.
- Palo Alto Investors opened 1 new position and closed 2 in Q3 2022.
- Palo Alto Investors's portfolio value rose 10% quarter-over-quarter to $1.26B.
Based on Palo Alto Investors's 13F filing for Q3 2022, filed 14 Nov 2022.